At week 40 , the proportion of patients with a PGA score of 0 or 1 remained significantly higher in the 50-mg , 100-mg , and 200-mg guselkumab groups than in the adalimumab group ( 71 % , 77 % , and 81 % , respectively , vs. 49 % ) ( P < 0.05 for all comparisons ) .